News

There are four key components at the root of the changing dynamic between payers and providers. Here’s what they are, and what to do about them.

The ER Savings Initiative is designed to deliver care in a hybrid model that collaborates with health systems to eliminate the unnecessary use and costs of their ERs.

Sterling Partners’ Dan Hosler identifies the subsectors for healthcare investing that can help reduce costs and improve quality.

In 2013, its first year taking part in CMS’ Shared Savings Accountable Care Organization (ACO) Program, Rio Grande Valley Health Providers saved nearly $12 million. Here, the CEO and CMO discusses the keys to success.

HHS has announced steps aimed at limiting short-term health plans and strengthening the marketplaces. Here's how you will be affected.

Teva Pharmaceuticals is temporarily suspending sales and distribution of its sumatriptan iontophoretic transdermal system (Zecuity) patch for migraines, after FDA said it is investigating the risk of serious burns with the use of the patch.

FDA approved the first US vaccine for cholera, Vaxchora, made by PaxVax Bermuda Ltd. in Hamilton, Bermuda. Vaxchora is the only single-dose vaccine for cholera currently licensed anywhere in the world.

Precision medicine isn’t just about genomics anymore. With the field moving forward as the next step in population health management, environmental, social and lifestyle factors that live outside the medical system are increasingly important to target treatments and engage patients. That means health plans also need innovative technology solutions to capture, store and integrate this crucial information.

The goal of CMS’ proposal is to reduce costs while rewarding better outcomes for patients. Here are five things healthcare executives need to know.

A KPMG expert discusses the biggest drivers and challenges for expediting the adoption of virtual care.

The transition to value-based payment has accelerated rapidly over the past two years, and payers and providers predict even more dramatic changes.

Making these three changes to health insurance exchange plan offerings could attract more consumers and increase the likelihood of success.

Physicians need to be well-versed in the evolving government requirements for billing, reimbursement and overall healthcare delivery/patient experience. One expert outlines these important items for physicians to watch.

Insurers are gaining trust while pharma moves backwards in trust. Find out why.

Medication non-adherence is a growing issue for patients, physicians and health plans. Here’s one effective solution.

Humana's Bold Goal progress report aims to improve population health by addressing health barriers, increasing access to healthcare, encouraging healthy behaviors, and promoting the prevention and management of chronic conditions prevention and management.

De-escalated maintenance or “drug holidays”: What’s best for patients with metastatic colorectal cancer?

Most patients hear the word “carcinoma” or “cancer” and believe they may die if they do not seek treatment. But ASCO researchers say that may be a problematic mentality.

Biosimilars will have a significant impact on cancer treatment, with the potential to drive cost savings, but will patients and providers be accepting?

FDA is warning consumers about the risk of serious bleeding when using over-the-counter aspirin-containing antacid products to treat heartburn. The agency also issued a separate warning about loperamide (Imodium, Johnson & Johnson), saying that abuse or misuse of the product can cause serious heart problems that can lead to death.

Health plans and healthcare organizations are increasingly facing threats from cyber criminals. Here's how to better protect your organization.

Targeted treatments of HER2-positive breast cancers have dramatically prolonged many patients’ lives. But treatment outcomes in clinical trial settings don’t always translate into comparable real-world clinical value.

Patient-reported outcomes are playing a growing role in cancer research and are poised to become an important part of regulatory review in drug development-and even routine clinical cancer care.

The first and only fixed-dose combination of a beta blocker beta blocker (BB) and angiotensin II receptor blocker (ARB) for hypertension will be available in the US in the second half of the year. FDA approved nebivolol and valsartan (Byvalson, Allergan) 5 mg/80 mg tablets in early June.

A look at how burnout affects providers, their patients, and the centers that employ them.

Expanded access or “compassionate use” programs allow patients to use investigational treatments, medical devices, or tests, before they have received FDA approval.

ASCO 2016 presenters share how combination therapies and biomarkers can better identify which tumors are likely to succumb to particular immunotherapies

FDA recently approved daclizumab (Zinbryta, Biogen and AbbVie), a once-monthly, self-administered, subcutaneous treatment for relapsing forms of multiple sclerosis (RMS).

The ACA has done a lot of good, but key opinion leaders believe there’s still room for improvement.

Determining what to measure, and how best to measure it, can be surprisingly complex-and appropriate metrics can vary between cancer types and patient populations.